White Paper Affirms Value of Orphan Drug Tax Credit in Promoting R&D

NORD and BIO (the Biotechnology Innovation Organization) have released a white paper examining the impact of the Orphan Drug Tax Credit (ODTC) on the development of treatments for rare diseases. The conclusion is that one-third fewer treatments would have been developed for rare diseases over the past 30 years without the ODTC. Read the white paper: http://rarediseases.org/odtcwhitepaper/

NORD and BIO (the Biotechnology Innovation Organization) have released a white paper examining the impact of the Orphan Drug Tax Credit (ODTC) on the development of treatments for rare diseases. The conclusion is that one-third fewer treatments would have been developed for rare diseases over the past 30 years without the ODTC. Read the white paper: http://rarediseases.org/odtcwhitepaper/

NORD and BIO (the Biotechnology Innovation Organization) have released a white paper examining the impact of the Orphan Drug Tax Credit (ODTC) on the development of treatments for rare diseases. The conclusion is that one-third fewer treatments would have been developed for rare diseases over the past 30 years without the ODTC. Read the white paper: http://rarediseases.org/odtcwhitepaper/